Loading...
XNASAKRO
Market cap1.99bUSD
Dec 24, Last price  
28.56USD
1D
0.67%
1Q
2.00%
IPO
44.97%
Name

Akero Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:AKRO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.89%
Rev. gr., 5y
%
Revenues
0k
Net income
-152m
L+39.34%
-4,564,000-81,714,000-43,755,000-79,190,000-100,736,000-108,910,000-151,759,000
CFO
-145m
L+57.12%
-4,382,000-4,625,000-35,627,000-70,804,000-79,681,000-92,517,000-145,367,000
Earnings
Feb 26, 2025

Profile

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
URL
https://www.akerotx.com/
IPO date
Jun 20, 2019
Employees
44
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
172,899
115,416
101,130
Unusual Expense (Income)
NOPBT
(172,899)
(115,416)
(101,130)
NOPBT Margin
Operating Taxes
(3,123)
(41)
Tax Rate
NOPAT
(172,899)
(112,293)
(101,089)
Net income
(151,759)
39.34%
(108,910)
8.11%
(100,736)
27.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
335,429
246,645
975
BB yield
-27.33%
-11.55%
-0.13%
Debt
Debt current
522
325
205
Long-term debt
26,602
12,024
2,827
Deferred revenue
Other long-term liabilities
54
305
Net debt
(542,169)
(339,100)
(185,226)
Cash flow
Cash from operating activities
(145,367)
(92,517)
(79,681)
CAPEX
Cash from investing activities
(223,623)
(63,825)
42,280
Cash from financing activities
353,316
255,632
602
FCF
(172,636)
(112,033)
(100,845)
Balance
Cash
550,010
351,449
188,258
Long term investments
19,283
Excess cash
569,293
351,449
188,258
Stockholders' equity
(573,820)
(422,295)
(310,327)
Invested Capital
1,135,485
760,107
480,952
ROIC
ROCE
EV
Common stock shares outstanding
52,568
38,985
34,827
Price
23.35
-57.39%
54.80
159.10%
21.15
-18.02%
Market cap
1,227,467
-42.54%
2,136,366
190.03%
736,599
-9.26%
EV
685,298
1,797,266
551,373
EBITDA
(172,870)
(115,373)
(101,089)
EV/EBITDA
Interest
3,099
739
Interest/NOPBT